PT3381942T - Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário - Google Patents

Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário

Info

Publication number
PT3381942T
PT3381942T PT181578428T PT18157842T PT3381942T PT 3381942 T PT3381942 T PT 3381942T PT 181578428 T PT181578428 T PT 181578428T PT 18157842 T PT18157842 T PT 18157842T PT 3381942 T PT3381942 T PT 3381942T
Authority
PT
Portugal
Prior art keywords
herpes simplex
simplex virus
immune checkpoint
checkpoint inhibitor
treating melanoma
Prior art date
Application number
PT181578428T
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49162279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3381942(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT3381942T publication Critical patent/PT3381942T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14341—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PT181578428T 2012-08-30 2013-08-30 Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário PT3381942T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261694963P 2012-08-30 2012-08-30
US201361846147P 2013-07-15 2013-07-15

Publications (1)

Publication Number Publication Date
PT3381942T true PT3381942T (pt) 2021-05-24

Family

ID=49162279

Family Applications (1)

Application Number Title Priority Date Filing Date
PT181578428T PT3381942T (pt) 2012-08-30 2013-08-30 Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário

Country Status (12)

Country Link
US (2) US10034938B2 (pt)
EP (3) EP3981791A1 (pt)
JP (2) JP6457940B2 (pt)
KR (2) KR20210008155A (pt)
CN (2) CN104704002B (pt)
AU (3) AU2013308595C1 (pt)
CA (1) CA2881851C (pt)
EA (1) EA201590451A1 (pt)
ES (1) ES2871910T3 (pt)
HK (1) HK1211601A1 (pt)
PT (1) PT3381942T (pt)
WO (1) WO2014036412A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210008155A (ko) 2012-08-30 2021-01-20 암젠 인크 단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
KR20160066554A (ko) 2013-10-25 2016-06-10 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
CA2947605A1 (en) 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
BR112016028255A2 (pt) 2014-06-06 2017-08-22 Flexus Biosciences Inc agentes imunorreguladores
CN106999577B (zh) * 2014-07-16 2021-12-21 特兰斯吉恩股份有限公司 溶瘤病毒和免疫检查点调节因子组合
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
WO2016057898A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
ES2882080T3 (es) * 2014-10-21 2021-12-01 Sciclone Pharmaceuticals Int Ltd Tratamiento del cáncer con estimuladores inmunitarios
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents
EP3234114B9 (en) * 2014-12-18 2023-06-14 Amgen Inc. Stable frozen herpes simplex virus formulation
CN117100753A (zh) * 2015-02-12 2023-11-24 大连万春布林医药有限公司 普那布林联合免疫检查点抑制剂的用途
CN107735103B (zh) 2015-02-25 2022-05-27 纪念斯隆-凯特琳癌症中心 使用灭活的非复制型的修饰的痘苗病毒安卡拉(mva)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合
US20180064662A1 (en) * 2015-03-05 2018-03-08 The General Hospital Corporation Novel compositions and uses of metformin agents
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
EP3294757B1 (en) 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
US11179385B2 (en) * 2015-06-30 2021-11-23 The Trustees Of The University Of Pennsylvania Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions
EP3217993A1 (en) * 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
WO2017079746A2 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
SG11201805556QA (en) 2016-01-08 2018-07-30 Momotaro Gene Inc A combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor
ES2943150T3 (es) 2016-01-08 2023-06-09 Replimune Ltd Cepa de virus oncolítico
KR20180133395A (ko) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
CA3015818A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Recombinant mva or mva.delta.e3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
EP4302782A3 (en) 2016-03-15 2024-03-27 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
JP7197370B2 (ja) * 2016-06-17 2022-12-27 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア がんの予防および／または治療のための化合物、組成物および方法
US11359017B2 (en) 2016-07-01 2022-06-14 Tohoku University Method of altering an antibody-related adverse event based on SCD163 and/or CXCL5 levels
EP3783032A1 (en) 2016-09-12 2021-02-24 Targovax Oy Combining adenovirus and checkpoint inhibitors for treating cancer
WO2018075447A1 (en) * 2016-10-19 2018-04-26 The Trustees Of Columbia University In The City Of New York Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
CA3056392A1 (en) * 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CN110678750A (zh) 2017-04-28 2020-01-10 美国默沙东药厂 用于癌症治疗的生物标志物
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN107354136A (zh) * 2017-06-15 2017-11-17 杭州睿可特生物科技有限公司 重组单纯疱疹病毒及其制备方法和应用
AU2018355519A1 (en) 2017-10-27 2020-03-26 Amgen Inc. Compositions and methods for treating liver cancer
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
US20220305127A1 (en) 2017-12-21 2022-09-29 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
CN108635380A (zh) * 2018-04-13 2018-10-12 北京唯源立康生物科技有限公司 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
CN110833622A (zh) * 2018-08-17 2020-02-25 北京奥源和力生物技术有限公司 用于治疗癌症的组合及其治疗用途
WO2020092385A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
CN113439123A (zh) * 2019-03-05 2021-09-24 安进公司 溶瘤病毒用于治疗癌症的用途
TW202102543A (zh) * 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
KR20240102682A (ko) 2022-12-26 2024-07-03 한국단자공업 주식회사 터미널 및 이 터미널을 구비한 커넥터

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
KR100768408B1 (ko) * 2000-01-21 2007-10-18 바이오벡스 리미티드 헤르페스 바이러스 주
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP6087503B2 (ja) 2008-09-26 2017-03-08 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
PT4209510T (pt) 2008-12-09 2024-04-02 Hoffmann La Roche Anticorpos anti-pm-l1 e a sua utilização para a melhoria do funcionamento das células t
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US20110118464A1 (en) * 2009-11-18 2011-05-19 Kaohsiung Medical University Halogenated xanthine derivatives and precursors thereof for anti-cancer and anti-metastasis activity and preparing method thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012122444A1 (en) * 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
EP2591796A1 (en) * 2011-11-10 2013-05-15 Universität Zürich Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
EP3578198A1 (en) * 2012-01-25 2019-12-11 DNAtrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
KR20210008155A (ko) 2012-08-30 2021-01-20 암젠 인크 단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
EP3552615B8 (en) * 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
EP3217993A1 (en) * 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
CA3056392A1 (en) * 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer

Also Published As

Publication number Publication date
EP3381942A1 (en) 2018-10-03
KR102204525B1 (ko) 2021-01-19
KR20150047512A (ko) 2015-05-04
JP6457940B2 (ja) 2019-01-23
EP3381942B1 (en) 2021-04-14
CN114984062A (zh) 2022-09-02
EP2890714A2 (en) 2015-07-08
JP2019065028A (ja) 2019-04-25
WO2014036412A3 (en) 2014-06-05
JP2015526525A (ja) 2015-09-10
EP3981791A1 (en) 2022-04-13
AU2013308595A1 (en) 2015-03-05
KR20210008155A (ko) 2021-01-20
AU2018208640A1 (en) 2018-08-09
JP6656349B2 (ja) 2020-03-04
CN104704002B (zh) 2022-05-10
CA2881851A1 (en) 2014-03-06
EA201590451A1 (ru) 2016-05-31
ES2871910T3 (es) 2021-11-02
HK1211601A1 (en) 2016-05-27
US20150202290A1 (en) 2015-07-23
AU2013308595B2 (en) 2018-04-26
CN104704002A (zh) 2015-06-10
US10034938B2 (en) 2018-07-31
CA2881851C (en) 2021-01-26
AU2013308595C1 (en) 2019-01-17
AU2020201051A1 (en) 2020-03-05
WO2014036412A2 (en) 2014-03-06
US20190060452A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
HK1211601A1 (en) A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
HK1213159A1 (zh) 用於處理表面的系統和方法
EP2798270A4 (en) METHOD AND APPARATUS FOR ENHANCING FLAME RADIATION
IL232376A0 (en) Payment system and method
EP2831822A4 (en) PAYMENT DEVICE AND METHOD
ZA201300806B (en) System and method for face capture and matching
EP2787476A4 (en) METHOD AND SYSTEM FOR SAFE MOBILE PORTFOLIO TRANSACTION
EP2745228A4 (en) DEVICE AND METHOD FOR SAFE ENERGY RECOVERY
GB201414970D0 (en) Fuel purchase transaction method and system
EP2831831A4 (en) SYSTEM AND METHOD FOR COMPENSATION TRANSACTIONS
HK1208741A1 (en) Method and system for authenticating a timepiece
EP2752638A4 (en) CONTACTLESS COMPONENT TESTING DEVICE AND COMPONENT TESTING METHOD
HK1213635A1 (zh) 用於驗證鐘錶的方法和系統
AP2015008237A0 (en) Methods and systems for treating a wellbore
GB2506273B (en) Methods and systems for creating structural documents
GB201115543D0 (en) Transaction system and method
EP2916483A4 (en) TRANSACTION SYSTEM AND TRANSACTION METHOD
GB201405448D0 (en) System and method for facilitating sales transaction
EP2850875A4 (en) METHOD AND APPARATUS FOR ENERGY SAVING
HK1208281A1 (en) Quick payment system and corresponding method
SG11201403934SA (en) Method and device for parallel scrambling
EP2912964A4 (en) MALE SURFACE ATTACHMENT, BOTTOM LAYER, AND FASTENING METHOD
HK1177237A1 (en) A covered walkway and a method for semi-precasting the same
GB2508477B (en) Computing apparatus and method
EP2885492A4 (en) METHOD AND DEVICE FOR SAFEGUARDING AND USING HYDROJET TOOLS